249 related articles for article (PubMed ID: 29204886)
1. Membrane-mediated amyloid deposition of human islet amyloid polypeptide.
Sasahara K
Biophys Rev; 2018 Apr; 10(2):453-462. PubMed ID: 29204886
[TBL] [Abstract][Full Text] [Related]
2. Amyloid aggregation and deposition of human islet amyloid polypeptide at membrane interfaces.
Sasahara K; Morigaki K; Shinya K
FEBS J; 2014 Jun; 281(11):2597-612. PubMed ID: 24702784
[TBL] [Abstract][Full Text] [Related]
3. Binding of islet amyloid polypeptide to supported lipid bilayers and amyloid aggregation at the membranes.
Sasahara K; Morigaki K; Okazaki T; Hamada D
Biochemistry; 2012 Sep; 51(35):6908-19. PubMed ID: 22876830
[TBL] [Abstract][Full Text] [Related]
4. Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus.
Caillon L; Hoffmann AR; Botz A; Khemtemourian L
J Diabetes Res; 2016; 2016():5639875. PubMed ID: 26636105
[TBL] [Abstract][Full Text] [Related]
5. Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in beta-cell death in type 2 diabetes mellitus.
Khemtémourian L; Killian JA; Höppener JW; Engel MF
Exp Diabetes Res; 2008; 2008():421287. PubMed ID: 18483616
[TBL] [Abstract][Full Text] [Related]
6. Recent computational studies of membrane interaction and disruption of human islet amyloid polypeptide: Monomers, oligomers and protofibrils.
Dong X; Qiao Q; Qian Z; Wei G
Biochim Biophys Acta Biomembr; 2018 Sep; 1860(9):1826-1839. PubMed ID: 29530482
[TBL] [Abstract][Full Text] [Related]
7. The N-terminal fragment of human islet amyloid polypeptide is non-fibrillogenic in the presence of membranes and does not cause leakage of bilayers of physiologically relevant lipid composition.
Khemtémourian L; Engel MF; Liskamp RM; Höppener JW; Killian JA
Biochim Biophys Acta; 2010 Sep; 1798(9):1805-11. PubMed ID: 20570648
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol modulates the interaction of the islet amyloid polypeptide with membranes.
Caillon L; Duma L; Lequin O; Khemtemourian L
Mol Membr Biol; 2014; 31(7-8):239-49. PubMed ID: 25495656
[TBL] [Abstract][Full Text] [Related]
9. Human islet amyloid polypeptide (hIAPP) aggregation in type 2 diabetes: Correlation between intrinsic physicochemical properties of hIAPP aggregates and their cytotoxicity.
Chaari A; Ladjimi M
Int J Biol Macromol; 2019 Sep; 136():57-65. PubMed ID: 31195047
[TBL] [Abstract][Full Text] [Related]
10. Interaction of hIAPP with model raft membranes and pancreatic beta-cells: cytotoxicity of hIAPP oligomers.
Weise K; Radovan D; Gohlke A; Opitz N; Winter R
Chembiochem; 2010 Jun; 11(9):1280-90. PubMed ID: 20440729
[TBL] [Abstract][Full Text] [Related]
11. Impaired processing of human pro-islet amyloid polypeptide is not a causative factor for fibril formation or membrane damage in vitro.
Khemtémourian L; Lahoz Casarramona G; Suylen DP; Hackeng TM; Meeldijk JD; de Kruijff B; Höppener JW; Killian JA
Biochemistry; 2009 Nov; 48(46):10918-25. PubMed ID: 19817482
[TBL] [Abstract][Full Text] [Related]
12. A single mutation in the nonamyloidogenic region of islet amyloid polypeptide greatly reduces toxicity.
Brender JR; Hartman K; Reid KR; Kennedy RT; Ramamoorthy A
Biochemistry; 2008 Dec; 47(48):12680-8. PubMed ID: 18989933
[TBL] [Abstract][Full Text] [Related]
13. Islet amyloid polypeptide inserts into phospholipid monolayers as monomer.
Engel MF; Yigittop H; Elgersma RC; Rijkers DT; Liskamp RM; de Kruijff B; Höppener JW; Antoinette Killian J
J Mol Biol; 2006 Feb; 356(3):783-9. PubMed ID: 16403520
[TBL] [Abstract][Full Text] [Related]
14. beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes.
Andrikopoulos S; Verchere CB; Terauchi Y; Kadowaki T; Kahn SE
Diabetes; 2000 Dec; 49(12):2056-62. PubMed ID: 11118007
[TBL] [Abstract][Full Text] [Related]
15. Fibril elongation by human islet amyloid polypeptide is the main event linking aggregation to membrane damage.
Elenbaas BOW; Kremsreiter SM; Khemtemourian L; Killian JA; Sinnige T
BBA Adv; 2023; 3():100083. PubMed ID: 37082256
[TBL] [Abstract][Full Text] [Related]
16. The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer's diseases.
Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Saad HM; Batiha GE
Diabetol Metab Syndr; 2023 May; 15(1):101. PubMed ID: 37173803
[TBL] [Abstract][Full Text] [Related]
17. Zinc boosts EGCG's hIAPP amyloid Inhibition both in solution and membrane.
Lee YH; Lin Y; Cox SJ; Kinoshita M; Sahoo BR; Ivanova M; Ramamoorthy A
Biochim Biophys Acta Proteins Proteom; 2019 May; 1867(5):529-536. PubMed ID: 30468883
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-induced β-cell dysfunction and islet inflammation are ameliorated by 4-phenylbutyrate (PBA) treatment.
Montane J; de Pablo S; Castaño C; Rodríguez-Comas J; Cadavez L; Obach M; Visa M; Alcarraz-Vizán G; Sanchez-Martinez M; Nonell-Canals A; Parrizas M; Servitja JM; Novials A
FASEB J; 2017 Dec; 31(12):5296-5306. PubMed ID: 28821639
[TBL] [Abstract][Full Text] [Related]
19. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction.
Westwell-Roper C; Dai DL; Soukhatcheva G; Potter KJ; van Rooijen N; Ehses JA; Verchere CB
J Immunol; 2011 Sep; 187(5):2755-65. PubMed ID: 21813778
[TBL] [Abstract][Full Text] [Related]
20. Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin.
Sellin D; Yan LM; Kapurniotu A; Winter R
Biophys Chem; 2010 Aug; 150(1-3):73-9. PubMed ID: 20153100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
